Skip to main content
TipRanks
Go Ultimate75% OFF

Medartis Holding AG (MED) Q2 2026 Earnings Report

2 Followers

CH:MED Q2 2026 EPS Results

Actual EPS
CHF 0.56
Consensus EPS
―
Beat/Miss
―
One Year Ago EPS
-CHF 0.03

CH:MED Q2 2026 Revenue Results

Actual Revenue
CHF 160.84M
Expected Revenue
CHF 152.40M
Beat/Miss
Beat by +CHF 8.44M
YoY Revenue Growth
+30.72%

Earnings Announcement Details

Quarter
Q2 2026
Date
08/18/2026
Time
Before Open
Conference Call
Tuesday, August 18, 2026
CH:MED Upcoming Earnings

Medartis Holding AG's next earnings date is estimated for March 2, 2027, based on past reporting schedules.

Q2 2026 Earnings Call Audio

No earnings call audio is available for this earnings event.

Q2 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q2 2026 Earnings Call Summary

Q2 2026
Earnings Call Date:Aug 18, 2026|% Change Since:29.92%|
Earnings Call Sentiment|Positive

The call conveyed a broadly positive outlook: material top-line acceleration (CHF 160.8m, +30.7%), stronger margins (core EBITDA margin 18%) and multiple successful product launches and capacity investments underpin a raised full-year revenue guidance to +17–19%. Key operational investments (plant expansions, Keri/NeoOrtho integration) are driving short-term cash outflows and created some one-off costs (tariff complexity, litigation posting, FX headwinds, distributor transitions), but management presented clear plans to localize production, scale TOUCH and convert pipeline initiatives. On balance the positives (robust growth, margin improvement, product momentum and strategic investments) outweigh the challenges, which are largely transitional or one-off in nature.

Company Guidance

Management raised 2026 full‑year core sales guidance to 17–19% growth and reiterated a core EBITDA margin in the “high teens” after a strong H1: group revenue CHF 160.8m (+30.7% y/y), organic growth 17%, H1 EBITDA margin 18% (core EBITDA CHF 28.8m) and core gross margin 81.5%; they lifted U.S. TOUCH units from 1,200 to 1,800 (≈700 performed in H1; ASP USD 6,500), which they say adds ~CHF 3m to full‑year revenue, and expect global TOUCH volume to rise from just over 40,000 last year to ~60,000 in 2026; operationally they plan ~70% of U.S. demand to be produced locally by year‑end (≈80% in 2027), see FY CapEx around CHF 35m (H1 CapEx ~CHF 18m), H1 free cash flow -CHF 10m (≈breakeven excluding ~CHF 10m extraordinary investment), ending cash CHF 26m, a normalized tax rate of ~12–12.5%, and recognized a CHF 4.4m tariff refund in H1.

  • Strong Top-Line GrowthGroup revenue CHF 160.8m, up 30.7% in CHF terms; organic revenue growth 17% driven by the U.S. and share gains in EMEA.
  • Improved ProfitabilityCore EBITDA margin increased to 18% (core EBITDA CHF 28.8m, +CHF 7m), with core net profit rising to ~CHF 7m (vs. a CHF 0.4m net loss prior year).
  • U.S. Acceleration and TOUCH MomentumU.S. sales up 27.4%; 700 TOUCH procedures performed in H1; guidance for U.S. TOUCH raised from 1,200 to 1,800 units for 2026 (ASP USD 6,500). TOUCH contributed materially to the upgraded outlook.
  • EMEA OutperformanceMultiple EMEA markets delivered strong double-digit growth (notably Germany, U.K., Spain and Austria ~20% growth in H1); EMEA posted the largest absolute sales increase (CHF 14m).
  • Product and Pipeline ProgressNew product launches and rollouts: Titan Nail launched (August), Proximal Humerus system in limited release, continued TOUCH expansion and CADskills acceptance—supporting future growth and cross-sell potential.
  • High Gross Margin and Margin DriversCore gross margin at 81.5% with a currency-adjusted improvement of ~140 basis points, driven by favorable product/price/regional mix and plant efficiency gains.
  • Inorganic Contributions and IntegrationM&A/inorganic contribution ~CHF 19m (NeoOrtho and Keri Medical); consolidation of Keri Medical is contributing to internal margin and revenue expansion.
  • Strategic Capacity InvestmentsSignificant capacity expansion underway: opened Curitiba facility (NeoOrtho), plant expansions in Archamps and Besancon, ramping production to localize supply (aim ~70% U.S. local production for U.S. sales by year-end).

CH:MED Earnings History

CH:MED earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 02, 20272026 (Q4)1.04-0.79――
Aug 18, 20262026 (Q2)―0.56-0.031956.67% (+0.59)
Mar 17, 20262025 (Q4)―0.790.08910.26% (+0.71)
Aug 19, 20252025 (Q2)―-0.030.19-115.79% (-0.22)
Mar 18, 20252024 (Q4)―0.080.12-34.45% (-0.04)
Aug 20, 20242024 (Q2)―0.19-0.07371.43% (+0.26)
Mar 12, 20242023 (Q4)―0.12-0.49124.34% (+0.61)
Aug 15, 20232023 (Q2)―-0.070―
Mar 14, 20232022 (Q4)―-0.49-0.02-2228.57% (-0.47)
Aug 16, 20222022 (Q2)―0.000.6-100.00% (-0.60)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed